Association of interleukin-10 gene variation with breast cancer prognosis

Breast Cancer Research and Treatment

Volumn 119, Issue 3, 2010, Pages 701-705

  Gerger, Armin ^a   Renner, Wilfried ^a   Langsenlehner, Tanja ^a   Hofmann, Günter ^a   Knechtel, Gudrun ^a   Szkandera, Joanna ^a   Samonigg, Hellmut ^a   Krippl, Peter ^b   Langsenlehner, Uwe ^c  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Internal Outpatient Department   (Austria)

Author keywords

Breast cancer; Interleukin; Polymorphism; Prognosis

Indexed keywords

DNA; ESTROGEN RECEPTOR; FOLIC ACID; INTERLEUKIN 10; PROGESTERONE RECEPTOR;

ADULT; AGED; ALLELE; APOPTOSIS; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DETOXIFICATION; DISEASE FREE SURVIVAL; DNA POLYMORPHISM; FEMALE; FOLATE METABOLISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSTAGLANDIN SYNTHESIS; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; HISTORY, 16TH CENTURY; HUMANS; INTERLEUKIN-10; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 74849109976     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0417-y     Document Type: Article

References (25)

1. B Rannala 2001 Finding genes influencing susceptibility to complex diseases in the post-genome era Am J Pharmacogenomics 1 3 203 221 10.2165/00129785-200101030-00005 10.2165/00129785-200101030-00005 1:CAS:528:DC%2BD38XlvVGluw%3D%3D 12083968
2. B Weigelt JL Peterse LJ van't Veer 2005 Breast cancer metastasis: markers and models Nat Rev Cancer 5 591 602 10.1038/nrc1670 10.1038/nrc1670 1:CAS:528:DC%2BD2MXmvVCltrg%3D 16056258 (Pubitemid 41081385)
3. DM Parkin F Bray J Ferlay, et al. 2002 Global cancer statistics CA Cancer J Clin 55 74 108 10.3322/canjclin.55.2.74 10.3322/canjclin.55.2.74
4. K Hunter 2005 The intersection of inheritance and metastasis: the role and implications of germline polymorphism in tumor dissemination Cell Cycle 4 12 1719 1721 1:CAS:528:DC%2BD28XktVChurk%3D 16294041
5. SM Hsieh NA Lintell KW Hunter 2007 Germline polymorphisms are potential metastasis risk and prognosis markers in breast cancer Breast Dis 26 157 162 1:STN:280:DC%2BD2s3msVKrug%3D%3D
6. K Hunter 2006 Breast host genetics influence tumour metastasis Nat Rev Cancer 6 2 141 146 10.1038/nrc1803 10.1038/nrc1803 1:CAS:528: DC%2BD28Xht1ems7w%3D 16491073 (Pubitemid 43361546)
7. BP Schneider M Wang M Radovich, et al. 2008 Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100 J Clin Oncol 26 28 4672 4678 10.1200/JCO.2008.16.1612 10.1200/JCO.2008.16.1612 1:CAS:528:DC%2BD1cXht1KqtLfE 18824714
8. HJ Lenz 2004 The use and development of germline polymorphisms in clinical oncology J Clin Oncol 22 13 2519 2521 10.1200/JCO.2004.04.900 10.1200/JCO.2004.04.900 1:CAS:528:DC%2BD2cXpsVWksrY%3D 15173210 (Pubitemid 41103738)
9. DF Hayes S Ethier ME Mippman 2006 New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK Breast Cancer Res Treat 100 237 238 10.1007/s10549-006-9253-5 10.1007/s10549-006-9253-5 16773436 (Pubitemid 44631926)
10. LM McShane DG Altman W Sauerbrei, et al. 2006 Reporting recommendations for tumor MARKer prognostic studies (REMARK) Breast Cancer Res Treat 100 229 235 10.1007/s10549-006-9242-8 10.1007/s10549-006-9242-8 16932852 (Pubitemid 44631925)
11. U Langsenlehner P Krippl W Renner, et al. 2003 The common 677C>T gene polymorphism of methylenetetrahydrofolate reductase gene is not associated with breast cancer risk Breast Cancer Res Treat 81 2 169 172 10.1023/A:1025752420309 10.1023/A:1025752420309 1:CAS:528:DC%2BD3sXntlGqt7w%3D 14572159 (Pubitemid 37211134)
12. U Langsenlehner P Krippl W Renner, et al. 2005 Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk Breast Cancer Res Treat 90 2 113 115 10.1007/s10549-004-3607-7 10.1007/s10549-004-3607-7 1:CAS:528:DC%2BD2MXivVKhs74%3D 15803357 (Pubitemid 40568894)
13. P Krippl U Langsenlehner W Renner, et al. 2004 Re: polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma J Natl Cancer Inst 96 19 1478 1479 15467038
14. P Krippl U Langsenlehner W Renner, et al. 2003 The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk Cancer Lett 201 2 181 184 10.1016/S0304-3835(03)00468-3 10.1016/S0304-3835(03)00468-3 1:CAS:528:DC%2BD3sXos1Kmt7k%3D 14607332 (Pubitemid 37357167)
15. U Langsenlehner P Krippl W Renner, et al. 2004 Genetic variants of the sulfotransferase 1A1 and breast cancer risk Breast Cancer Res Treat 87 1 19 22 10.1023/B:BREA.0000041574.90735.ea 10.1023/B:BREA.0000041574.90735.ea 1:CAS:528:DC%2BD2cXnsFOqtr8%3D 15377847 (Pubitemid 39237779)
16. U Langsenlehner B Yazdani-Biuki T Eder, et al. 2006 The cyclooxygenase-2 (PTGS2) 8473T>C polymorphism is associated with breast cancer risk Clin Cancer Res 12 4 1392 1394 10.1158/1078-0432.CCR-05-2055 10.1158/1078-0432.CCR- 05-2055 1:CAS:528:DC%2BD28XhsFalurk%3D 16489098 (Pubitemid 43342533)
17. A Gerger U Langsenlehner W Renner, et al. 2007 A multigenetic approach to predict breast cancer risk Breast Cancer Res Treat 104 2 159 164 10.1007/s10549-006-9408-4 10.1007/s10549-006-9408-4 1:CAS:528: DC%2BD2sXnvFKnu7s%3D 17058024 (Pubitemid 47084229)
18. S Mocellin F Marincola CR Rossi, et al. 2004 The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle Cytokine Growth Factor Rev 15 61 76 10.1016/j.cytogfr.2003.11.001 10.1016/j.cytogfr.2003.11.001 1:CAS:528:DC%2BD2cXmvFKktQ%3D%3D 14746814 (Pubitemid 38121291)
19. DF Fiorentino A Zlotnik TR Mosmann, et al. 1991 IL10 inhibits cytokine production by activated macrophages J Immunol 147 3815 3822 1:CAS:528: DyaK38XlslSgug%3D%3D 1940369
20. DM Turner DM Williams D Sankaran, et al. 1997 An investigation of polymorphism in the interleukin-10 gene promoter Eur J Immunogenet 24 1 8 1:CAS:528:DyaK2sXhsFCjsL0%3D 9043871
21. E Crawley R Kay J Sillibourne, et al. 1999 Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis Arthritis Rheum 42 1101 1108 10.1002/1529-0131(199906)42: 6<1101::AID-ANR6>3.0.CO;2-Y 10.1002/1529-0131(199906)42:6<1101::AID- ANR6>3.0.CO;2-Y 1:CAS:528:DyaK1MXktVegt70%3D 10366102 (Pubitemid 29268946)
22. MT Lin B Storer PJ Martin, et al. 2003 Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation N Engl J Med 349 2201 2210 10.1056/NEJMoa022060 10.1056/NEJMoa022060 1:CAS:528:DC%2BD3sXps1Wjsr8%3D 14657427 (Pubitemid 37485136)
23. E Holler MG Roncarolo R Hintermeier-Knabe, et al. 2000 Prognostic significance of increased IL10 production in patients prior to allogeneic bone marrow transplantation Bone Marrow Transplant 25 237 241 10.1038/sj.bmt.1702126 10.1038/sj.bmt.1702126 1:STN:280:DC%2BD3c7jvFemsQ%3D%3D 10673693
24. SP Balasubramanian IA Azmy SE Higham, et al. 2006 Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review BMC Cancer 6 188 10.1186/1471-2407-6-188 10.1186/1471-2407-6-188 1:STN:280:DC%2BD28rgs1aqug%3D%3D 16842617 (Pubitemid 44295087)
25. WM Howell MJ Rose-Zerilli 2006 Interleukin-10 polymorphisms, cancer susceptibility and prognosis Fam Cancer 5 2 143 149 10.1007/s10689-005-0072-3 10.1007/s10689-005-0072-3 1:CAS:528:DC%2BD28XltFWksbY%3D 16736283 (Pubitemid 43824470)